Targeting tau starts to show results in Alzheimer's
This article was originally published in Scrip
Two compounds designed to tackle the tau pathology of Alzheimer's disease, TauRx Therapeutics' Rember and Allon Therapeutics' AL-108, have shown encouraging results in Phase II data presented at the International Conference on Alzheimer's Disease in Chicago.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.